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A simple, rapid and selective method using high-performance liquid chromatography with ultraviolet detection (267 nm) was applied 
for the determination of tryptophan in plasma. Separation was carried out on a C18 column (150 x 4.6 mm internal diameter) in 6 
min. The mobile phase consisted of 5 mM the sodium acetate and acetonitrile (92:8, v/v). The method was shown to be precise and 
accurate, and good recovery of analyte was achieved, characterizing the method as efficient and reliable for use in laboratory analysis.
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INTRODUCTION
Tryptophan (Figure 1) is an essential human amino acid that acts 
predominantly as the precursor of serotonin (5-HT), an important neu-
rotransmitter with physiological activity.1 It has a role in physiological 
(nerve transmission, immune response) and pathological processes 
(depression, stress, and sleep and appetite disorders)2 and therefore 
its plasma levels are linked to changes in mood, behavior, anxiety, 
sleep, fatigue and appetite suppression.3 These characteristics have 
led research centers to focus their studies on the creation of methods 
allowing the determination and quantification of this amino acid, as 
well as the identification of possible relationships between plasma 
levels of tryptophan with diseases and metabolic disorders.
Various methods and techniques for quantifying these tryptophan 
plasma levels have been developed over the years, such as direct 
spectrophotometric analysis, colorimetric methods,4 electrospray 
ionization tandem mass spectrometry5 and high performance liquid 
chromatography (HPLC). This latter approach become the technique 
of choice for analysis, because of its speed, efficiency and excellent se-
paration for both the amino acid and its metabolites.6 In methods using 
this technique, different detectors have been described, namely: mass 
spectrometry,5,7 fluorescence,1,8,9 fluorimetric 10 and ultraviolet.11,12
Given the importance of tryptophan in various human physio-
logical functions and the methods available in the literature, we 
sought through this work to develop a simple and rapid method for 
quantification of tryptophan in human plasma using HPLC technique 
with photodiode array (PDA) detection. Quantification in humans can 
aid the understanding of the pathophysiology of depression and other 
psychiatric disorders, and serves to assess the nutritional content of 
the diet of patients who have a predisposition to low 5-HT plasma 
levels. In addition, the reduced use of organic solvents of the proposed 
technique provides economy for laboratories and generates residues 
less harmful to the environment.
EXPERIMENTAL
Reagents and materials
All reagents were of analytical grade and solvents were of chro-
matography purity. The sodium acetate and perchloric acid were from 
Merck (Darmstadt, Germany), the acetonitrile from Tedia (Fairfield, 
USA) and L-tryptophan (98% purity), used as standard substance was 
kindly donated as a gift by Ajinomoto (São Paulo, Brazil). Freshly 
prepared ultrapure water was obtained in-house using a Master Sys-
tem purification device from Gehaka (São Paulo, Brazil).
Standard preparation
A tryptophan stock solution was prepared at a concentration of 
0.04 mg mL-1 in mobile phase. Throughout the assay, working solu-
tions were prepared from the stock solution, diluted in human plasma 
to concentrations of 0.5, 2.5, 5.0, 7.5, 15.0, 25.0 and 30.0 μg mL-1, 
according to the necessity of each validation test, and used fresh for 
each analysis.
Sample treatment
Eight patients were selected from a psychiatric clinic and basic 
health units and underwent two tests. The difference between the tests 
was the presence or absence of tryptophan in the mixture of amino 
acids to be ingested by the patients (namely tryptophan depletion, TD). 
Samples were collected at 8:30 am for determination of tryptophan 
baseline parameters. At 9:00 am, a mixture of amino acids (with or 
without tryptophan, according to the phase of the study) was adminis-
tered to the patients. At 3:30 pm, a further collection was performed 
to determine the occurrence of depletion of tryptophan basal levels in 
relation to the baseline measurements obtained at 8:30 am.13
The collection was carried out by venipuncture in vacutainer 
tubes containing ethylenediamine tetraacetic acid (EDTA) solution as 
the anticoagulant. After centrifugation of the blood, the plasma was 
transferred to glass tubes and stored at –80 ºC until analysis. Prior to 
analysis, the plasma (500 μL) was subjected to deproteinization with 
Figure 1. Chemical structure of tryptophan (C11H12N2O2)
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8% perchloric acid (50 μL) solution,14 vortexed for 1 min and finally 
centrifuged for 15 min at 1200 x g, thermostatted at 4 ºC. A volume 
of 25 μL of the supernatant was injected into the HPLC system.
This experimental protocol was established in accordance with 
the Declaration of Helsinki and was approved by the Research Ethics 
Committee of the University of São Paulo (Approval no. 538/05).
Chromatographic conditions
Liquid chromatography was carried out on a Shimadzu (Tokyo, 
Japan) high performance liquid chromatography system equipped 
with a diode array SPD-10A vp detector set at 267 nm. Separation was 
carried out in a C18 (150 x 4.6 mm, 5 μm particle size) column from 
Nova Analítica (São Paulo, Brazil), maintained at room temperature. 
For the robustness study, a CLC-CN Shimadzu column (150 x 4.6 mm, 
5 μm particle size) was again used. The mobile phase consisted of an 
aqueous solution of sodium acetate (AcNa) (5 mM) and acetonitrile 
(ACN) (92:8, v/v), pH = 7.15. The flow rate was adjusted to 1 mL 
min-1 in an isocratic elution. Data acquisition and interpretation were 
performed using CLASS-Vp version 5.42 software.
Method validation
The method was fully validated for the parameters: linearity, 
limit of detection (LOD), limit of quantification (LOQ), specificity, 
precision, accuracy, stability, recovery and robustness.15
The linearity of the method was evaluated through the prepara-
tion of standard solutions of tryptophan in blank human plasma at 
concentrations of 0.5, 7.5, 15.0, 25.0 and 30.0 μg mL–1. Within this 
aim, values of each concentration level were statistically evaluated 
using analysis of variance (ANOVA)16 and the value of the correlation 
coefficient of the analytical curve.
The limit of detection (LOD) was estimated mathematically as three 
times the standard deviation of the y-intercept, the result being divided 
by the slope of the calibration curve. The limit of quantification (LOQ) 
was calculated as ten times the standard deviation of the y-intercept, 
the result being divided by the slope of the calibration curve.15
The specificity was evaluated comparing the retention time of 
the tryptophan standard substance spiked in lipemic, hemolysate and 
natural plasma samples, to prove that the method provides selective 
and specific determination of tryptophan.
The precision study comprised repeatability (intra-day precision) 
and intermediate precision (inter-day precision) studies. The intra-day 
precision was estimated on three concentrations of tryptophan (2.5, 
5.0 and 15.0 μg mL–1) and determined in five samples in a day, while 
inter-day precision was determined by measuring the same sample 
on three consecutive days.
The accuracy of the method was determined through the analysis 
of the plasma samples spiked with the tryptophan standard substance, 
at three different concentrations: 2.5, 5.0, 15.0 μg mL– 1 (n = 5, for 
each concentration). 
Stability of the working solutions (biological matrix and standard 
solution) was evaluated under the following storage conditions: room 
temperature (18 ºC) for 24 h; 4 ºC for 7, 15 and 30 days, –20 ºC for 
7, 15 and 30 days, and –80 ºC for 30 days.
Recovery was estimated by the chromatographic analyses of pool 
plasma before and after the spiking of standard solutions of trypto-
phan, in the concentrations of 5.0, 10.0 and 25.0 μg mL–1. Sample 
recovery was expressed as: {[(experimental concentration - pool 
plasma concentration) /spiked amount] x 100}.
The robustness of the method was evaluated by varying method 
parameters such as mobile phase and its flow rate as well as the 
packing of the chromatographic columns.
RESULTS AND DISCUSSION
Several methods have been reported for the determination of 
tryptophan in human plasma by HPLC, which has become the 
technique of choice for this amino acid.1,4,8,11,14,17 However, the chro-
matographic techniques are well-known for their use (sometimes in 
large quantities) of environmentally hazardous organic solvents and 
can affect human health.18 Current recommendations encouraged the 
use of smaller amounts of these solvents (or none), aiming to achieve 
safer methods of analysis, without compromising their performance: 
this can be considered the pillar of the so-called “green chemistry”.19
A typical chromatogram obtained with extracted plasma sample 
spiked with the tryptophan standard substance is shown in Figure 2, 
where the good retention time (tR) of 5.1 min can be observed. As 
the patients were subjected to other treatments (concurrent adminis-
tration of fluoxetine, sertraline, paroxetine or citalopram) during the 
experiment, a pool of their plasma before tryptophan administration 
was obtained and injected into the chromatograph. The blank human 
sample chromatogram can be observed in Figure 2, and confirms no 
interference in tryptophan retention time.
In the present work, the chromatographic runs were completed in 
10 min, despite the 5-min tryptophan retention time. This was done 
for academic purposes, to verify whether other compounds would be 
detectable by the method, which proved not the case. However, in the 
laboratory routine the runs can be completed in 6 min, a plausible and 
short time for an HPLC method for a biological matrix.
The calibration curve was obtained through experiments perfor-
med in duplicate, and yielded the statistical model: y (± 3591.22) 
= 29976.76 (± 86.79) x – 1026.19 (± 1649.75), with R2 = 0.99993. 
The linearity of the method was also evaluated through analysis of 
variance, as shown in Table 1.
The test of significance of regression gave the value of 
Fcalculated (MS model / MS residual) = 119289.08, larger than Fcritical 0.05, v1=1, v2=8 = 
5.32, which confirms the existence of a significant linear relationship 
between the two variables, with 95% confidence. The test of lack of 
fit returned the value of Fcalculated (MSl ack of fit/MS pure error) = 5.55, larger than 
Figure 2. Chromatogram of: (A) tryptophan standard solution, at a concen-
tration of 2.5 µg mL-1; and (B) blank human plasma
Table 1. Analysis of variance for fitting the model of prediction for the 
validation study
Source Sum of Square 
(SS)
Number of degrees  
of freedom
Mean of Square 
(MS)
Model 1.06 × 1012 1 1.06 × 1012
Residual 7.10 × 107 8 8.88 × 106
Lack of fit 5.46 × 107 3 1.82 × 107
Pure error 1.64 × 107 5 3.28 × 106
Total 1.06 × 1012 9 1.06 × 1012
% variation explained by regression = 99.99; % maximum of variation ex-
plained = 99.99
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Fcritical 0.05, v1=3, v2=5 = 5.41, with 95% confidence. Through these results, 
one can observe that there is lack of fit in the method, however the 
percentage of explained variation is very close (mathematically 
equal) to the maximum that can be applied by the model. Thus, the 
results upon using the equation of the model to predict tryptophan 
concentrations will be very close to the real values in the samples.
The LOD was 0.27 μg mL–1 of tryptophan and the LOQ was 
0.50 μg mL–1 (coefficient of variation, CV, = 1.98% and standard 
deviation, SD, = 0.01, for five replicates). 
The specificity of the method was obtained through the com-
parison among the sample chromatograms of natural, lipemic and 
hemolysate plasmas spiked with tryptophan, and no other peak was 
observed near its retention time, as shown in Figure 3. The plasma 
samples, spiked with tryptophan at the following concentrations: natu-
ral (2.5 g mL–1), lipemic (7.5 μg mL–1), and hemolysate (7.5 mg mL–1), 
were individually injected into the chromatograph. Through this test 
and the blank human plasma chromatogram (Figure 2), it was obser-
ved that there is no endogenous component of the biological matrix 
that prevents the detection/ quantification of tryptophan.
The precision of the method was calculated from intra- and 
inter-day measurements for three concentrations (2.5, 5.0 and 15.0 
μg mL–1), as shown in the Table 2.
The accuracy of the method was found to be 104.13% at the level 
of 2.5 μg mL–1, 99.54% at the level of 5.0 μg mL–1 and 100.78% at the 
level of 15.0 μg mL–1, in relation to the spiked amount of tryptophan 
in the samples.
With regard to stability, tryptophan standard solutions in mobile 
phase remained stable for 6 h at room temperature, and for 7 days at 
–20 ºC. In plasma, stability was verified as only 2 h at room tempera-
ture. Between –20 and –80 ºC the tryptophan did not present stability, 
because there was loss ≥ 10% in the value of the concentration of the 
sample compared with the measured value before storage. 
The recovery of the method was estimated by spiking the 
tryptophan standard in plasma at concentrations of 5.0, 10.0 and 
25.0 μg mL–1. The recovery results found for the samples were within 
the range of 94.32-99.80% (CV < 2.00%).
To evaluate robustness, the following parameters were tested: ef-
fect of the content of organic solvent in the mobile phase, effect of flow 
rate of the mobile phase and packing of the chromatographic column 
(porous silica particles bonded to octadecyl silane – C18 – or to nitrile 
groups – CN). The standard solutions of tryptophan were analyzed 
and tested using the mobile phase containing different amounts of 
ACN (1, 2 and 8%). With increasing amounts of ACN retention time 
decreased. Using the mobile phase containing 8% ACN, the peak 
area was increased, but the mobile phase containing only acetate 
buffer or 1% ACN did not elute the tryptophan. Retention time was 
decreased by increasing the flow rate to 1.5 mL min–1. In addition, 
no chromatographic peak was observed when using the CN column.
Thus, mobile phase consisted of a 5 mM sodium acetate - aceto-
nitrile (92:8, v/v) solution, flow-rate of 1 mL min-1 and the analytical 
column C18 were characterized as optimal conditions for the imple-
mentation of the analytical method in terms of selectivity, acceptable 
precision and accuracy. In addition, it is worth emphasizing the small 
percentage of acetonitrile used by the method compared with other 
robust methods that use large amounts of organic solvent.
After the validation process, plasma samples from the patients 
were submitted to quantification of tryptophan. Patients submitted to 
ingestion of the mixture not containing tryptophan (TD) had plasma 
concentrations ranging from 3.08 to 7.81 μg mL–1 (8:30 am) and be-
tween 0 and 4.79 μg mL–1 (3:30 pm). Patients who drank the mixture 
containing tryptophan had plasma concentrations ranging from 3.02 
to 8.90 μg mL–1 (8:30 am) and from 5.69 to 18.70 μg mL–1 (3:30 pm). 
The individual results are shown in Table 3.
In this study, the results of tryptophan plasma levels in patients 
undergoing TD showed significant differences in relation to the two 
Table 2. Precisions of intra-day and inter-day determination of plasma 
tryptophan
Concentration 
(μg mL–1)
Meann 
(μg mL–1)
SD 
(μg mL–1)
CV 
(%)
Intra-day (n=5)
2.5 2.60 0.01 0.26
5.0 4.97 0.03 0.72
15.0 15.11 0.20 1.30
Inter-day (n=15)
2.5 2.54 0.10 3.97
5.0 4.88 0.16 3.29
15.0 14.80 0.45 3.07
n = number of analyzed samples; SD, standard deviation; CV, coefficient 
of variation.
Figure 3. Chromatographic profile of plasma samples spiked with tryptophan 
at the following concentrations: natural (2.5 g mL–1), lipemic (7.5 µg mL–1), 
and hemolysate (7.5 mg mL–1)
Table 3. Tryptophan plasma level determined from patients samples
Patients
Mixture of amino acid without tryptophan Mixture of amino acid with tryptophan
Plasma level 
(μg mL–1)
8:30 am
Plasma level 
(μg mL–1)
3:30 pm
Plasma level 
(μg mL–1)
8:30 am
Plasma level 
(μg mL–1)
3:30 pm
1 5.66 2.97 8.90 18.70
2 3.08 1.13 4.39 9.29
3 6.83 4.79 3.98 5.69
4 6.30 not detectable 5.93 8.22
5 2.25 not detectable 8.87 14.98
6 7.81 not detectable 6.83 10.12
7 4.42 not detectable 3.02 7.28
8 5.05 not detectable 6.25 9.07
samples analyzed in duplicate.
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scheduled times in the test. The patients who ingested a mixture of 
amino acids that did not contain tryptophan had reduced or undetec-
table plasma levels - compared to patients who ingested a mixture 
containing tryptophan.
It was observed therefore that the determination of plasma levels 
of tryptophan can be used successfully to further understanding of the 
pathophysiology of depression and to investigate psychiatric disor-
ders. The method also allows assessments to be made regarding the 
nutritional content of the diet of patients who have a predisposition 
to low 5-HT plasma levels. The method proposed in this work is ap-
plicable for the determination of tryptophan in human plasma, since 
it proved able to quantify the amino acid in the biological matrix.
CONCLUSIONS 
The method proposed in this work is applicable for the deter-
mination of tryptophan in human plasma, since it proved able to 
quantify the amino acid in the biological matrix. The presented me-
thod is simple, rapid and accurate, and is not subject to interference 
of other molecules that absorb in the ultraviolet region. In addition, 
the method is environmentally-friendly due to the small amount of 
organic solvent needed in the mobile phase. The lower use of organic 
solvents also provides greater economy.
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